779 results on '"Kuendgen, A."'
Search Results
52. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy
53. Impact on survival of different treatments for myelodysplastic syndromes (MDS)
54. Nonrepetitive colorings of graphs of bounded tree-width
55. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia
56. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine
57. Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome
58. Current status of epigenetic treatment in myelodysplastic syndromes
59. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification
60. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
61. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
62. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
63. Therapy-related myeloid neoplasms following treatment with radioiodine
64. Treatment of Hematologic Malignancies with DNA Hypomethylating Agents
65. Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
66. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
67. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
68. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
69. Neut-X can be successfully used as diagnostic and prognostic tool in MDS
70. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome
71. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
72. Topic: AS02-Epidemiology
73. Chronic myelomonocytic leukemia in the light of the WHO proposals
74. Allogeneic stem cell transplantation in patients with therapy-related MDS/AML following treatment with radioiodine: P1169
75. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
76. Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes
77. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes
78. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes
79. Prognostic Factors and their Relevance in Different Subgroups of Myelodysplastic Syndromes - An Analysis of 2553 Patients from the Düsseldorf MDS Registry: V373
80. Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)
81. Reply to Valproic Acid for the Treatment of Myeloid Malignancies
82. Neut-X can be successfully used as diagnostic and prognostic tool in MDS
83. Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes
84. Valproic acid for the treatment of myeloid malignancies
85. Is lenalidomide a new standard treatment for myelodysplastic syndrome?
86. Myelodysplastic Syndromes in Patients Younger Than Age 50
87. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation
88. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
89. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals
90. Distinct Gene Expression Pattern of Malignant Hematopoietic Stem and Progenitor Cells in Polycythemia Vera
91. Treatment of Acute Myeloid Leukemia with Valproic Acid Alone or in Combination with All-trans-Retinoic Acid: O392
92. Polycythemia Vera CD34+ Cells Overexpress Retinoid Receptors and their Clonogeneic Growth Can Be Inhibited by All-Trans Retinoic Acid: O362
93. Valproic Acid Alone or in Combination with All-trans-Retinoic Acid (ATRA) for the Treatment of Myelodysplastic Syndromes: O357
94. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
95. Time-dependent changes in mortality and transformation risk in MDS
96. Romiplostim in Low/INT-1-Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Results from a Randomized, Double-Blind, Placebo-Controlled Study
97. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
98. Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS
99. Minimum average distance subsets in the hamming cube
100. Change of prognosis of patients with myelodysplastic syndromes during the last 30 years
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.